Drugs / BMS-986523
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07223047 | Nov 2025 → Oct 2028 expected | colorectal cancer, high grade malignant neoplasm, non-small cell lung carcinoma, pancreatic ductal adenocarcinoma | Bristol-Myers Squibb | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BMS-986523 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07223047 ↗ |